Acinetobacter baumannii:: a universal threat to public health?

被引:173
作者
Giamarellou, Helen [1 ]
Antoniadou, Anastasia [1 ]
Kanellakopoulou, Kyriaki [1 ]
机构
[1] Univ Gen Hosp ATTIKON, Dept Internal Med 4, Athens 12462, Greece
关键词
Acinetobacter baumannii; epidemiology; multiresistance; risk factors; clinical impact; therapy;
D O I
10.1016/j.ijantimicag.2008.02.013
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Acinetobacter spp. are non-fermentative, strictly aerobic, Gram-negative microorganisms with a confusing taxonomic history. The Acinetobacter baumannii-Acinetobacter calcoaceticus complex is the species most commonly isolated from clinical specimens. It is ubiquitous in nature and has been found as part of the normal skin, throat and rectal flora as well as in food and body lice. It colonises patients in Intensive Care Units and contaminates inanimate hospital surfaces and devices as well as wounds, including war injuries. Although a frequent coloniser, Acinetobacter can be the cause of severe and sometimes lethal infections, mostly of nosocomial origin, predominantly ventilator-associated pneumonia. Bacteraemic infections are rare but may evolve to septic shock. Acinetobacter also emerges as a cause of nosocomial outbreaks and is characterised by increasing antimicrobial multiresistance. Antibiotic use, especially carbapenems and third-generation cephalosporins, is recognised as the most important risk factor for multiresistance. Described resistance mechanisms include hydrolysis by beta-lactamases, alterations in outer membrane proteins and penicillin-binding proteins, and increased activity of efflux pumps. Today, Acinetobacter resistant to carbapenems, aminoglycosides and fluoroquinolones presents a challenge to the clinician. However, sulbactam, tigecycline and colistin represent the current therapeutic approaches, which are associated with satisfactory efficacy. (C) 2008 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:106 / 119
页数:14
相关论文
共 150 条
  • [1] BSAC standardized disc susceptibility testing method
    Andrews, JM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 : 43 - 57
  • [2] Community-acquired bacteremic Acinetobacter pneumonia in tropical Australia is caused by diverse strains of Acinetobacter baumannii, with carriage in the throat in at-risk groups
    Anstey, NM
    Currie, BJ
    Hassell, M
    Palmer, D
    Dwyer, B
    Seifert, H
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (02) : 685 - 686
  • [3] Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii
    Arroyo, LA
    García-Curiel, A
    Pachón-Ibañez, ME
    Llanos, AC
    Ruiz, M
    Pachón, J
    Aznar, J
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (02) : 903 - 905
  • [4] The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: Analysis of pooled clinical trial data
    Babinchak, T
    Ellis-Grosse, E
    Dartois, N
    Rose, GM
    Loh, E
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 41 : S354 - S367
  • [5] Prevalence and antimicrobial patterns of Acinetobacter baumannii on hands and nares of hospital personnel and patients:: The iceberg phenomenon again
    Bayuga, S
    Zeana, C
    Sahni, J
    Della-Latta, P
    El-Sadr, W
    Larson, E
    [J]. HEART & LUNG, 2002, 31 (05): : 382 - 390
  • [6] Acinetobacter spp, as nosocomial pathogens: Microbiological, clinical, and epidemiological features
    BergogneBerezin, E
    Towner, KJ
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 1996, 9 (02) : 148 - +
  • [7] Distribution of Acinetobacter species on skin of healthy humans
    Berlau J.
    Aucken H.
    Malnick H.
    Pitt T.
    [J]. European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18 (3) : 179 - 183
  • [8] Isolation of Acinetobacter spp including A-baumannii from vegetables:: implications for hospital-acquired infections
    Berlau, J
    Aucken, HM
    Houang, E
    Pitt, TL
    [J]. JOURNAL OF HOSPITAL INFECTION, 1999, 42 (03) : 201 - 204
  • [9] In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain
    Betriu, C
    Rodríguez-Avial, I
    Sánchez, BA
    Gómez, M
    Alvarez, J
    Picazo, JJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 892 - 895
  • [10] High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii
    Betrosian, Alex P.
    Frantzeskaki, Frantzeska
    Xanthaki, Anna
    Georgiadis, George
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2007, 39 (01) : 38 - 43